Ampligen rintatolimod: Phase II started

Last month, Hemispherx said it began the Phase II portion of a double-blind, placebo-controlled, U.S. Phase I/II trial comparing nasal adjuvant Ampligen plus FluMist vs. FluMist alone in 72 healthy volunteers. The Phase II portion will enroll 60 patients. ...